Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation - PubMed
3 days ago
- #Synthetic Lethality
- #Endometrial Cancer
- #PRMT5 Inhibition
- Inhibition of PRMT5 causes synthetic lethality in ARID1A-deficient endometrial cancer by increasing aberrant R-loop accumulation.
- The study was approved by the Animal Ethics Committee of Tongji Medical College and the Institutional Ethics Committee, following the Declaration of Helsinki.
- Endometrial cancer and normal tissues were sourced from Union Hospital, Huazhong University of Science and Technology, with informed consent from participants.
- Patient-derived organoids (PDOs) were established with ethical approval (CTOB-2025-0917).
- Authors declare no competing interests and consent to publication.
- References highlight advances in endometrial cancer management, diagnosis challenges, drug discovery, and immunotherapy combinations.